Tuesday, January 22, 2019 12:50:49 PM
JANUARY 18, 2019
Common food additives may promote anxiety-related behavior and reduce social behavior in mice, research shows
by Jennifer Rainey Marquez, Georgia State University
Credit: Georgia State University
Food additives known as dietary emulsifiers, commonly found in processed foods to improve texture and extend shelf life, may adversely affect anxiety-related and social behaviors in mice, Georgia State researchers have found.
The scientists also observed sex differences in the mice's behavioral patterns, suggesting that emulsifiers affect the brain via distinct mechanisms in males and females.
The study, published in Scientific Reports, was led by Geert de Vries, professor of neuroscience and associate vice president for research at Georgia State, and Benoit Chassaing, assistant professor of neuroscience. Andrew T. Gewirtz, professor in the Institute for Biomedical Sciences, also contributed.
Previous research by Chassaing and Gewirtz has shown that emulsifiers can cause low-grade intestinal inflammation by altering the composition of gut microbiota, a diverse population of trillions of microorganisms that are vital to health. Their research has linked emulsifier consumption to obesity, metabolic syndrome and inflammatory bowel diseases such as colitis, conditions whose incidence has significantly increased since the mid-20th century.
In the same period there has also been an increased incidence of behavioral disorders such as autism, leading scientists to theorize that brain function may be affected by environmental exposure to modern chemical substances as well.
"We asked the question: Can emulsifiers' effects on general systemic inflammation also be extended to the brain and to behavior?" de Vries said. "The answer was yes."
The researchers added one of two commonly used emulsifiers, polysorbate 80 and carboxymethylcellulose, to the drinking water of male and female mice. After 12 weeks, they observed that treatment with emulsifiers altered the gut microbiota of males and females in different ways. They then conducted tests to assess the effects of the emulsifiers on behavior. The researchers found that emulsifiers altered anxiety-like behavior in male mice and reduced social behavior in female mice.
Though de Vries says he cannot pinpoint the exact mechanism by which emulsifiers contribute to behavioral changes, "we know that inflammation triggers local immune cells to produce signaling molecules that can affect tissues in other places, including the brain," he said. "The gut also contains branches of the vagus nerve, which forms a direct information pathway to the brain."
"We are currently investigating the mechanisms by which dietary emulsifiers are impacting the intestinal microbiota as well as the human relevance of those findings," Chassaing said.
As to what's driving the differences between male and female behavior, de Vries said there may be several factors. For example, there are known sex differences in the immune system, which help govern the composition of bacteria in the gut, and in the way the digestive system processes food.
As a result, "adding emulsifiers to the diet will have different consequences for the microbiota of males and females," he said. "Our data suggest that these sex-specific changes to the microbiota could contribute to the sex differences in behavior."
The researchers say the study adds to evidence that food additives should be evaluated for their effect on the microbiome, which is tied up in many aspects of human health. De Vries said the results also confirm that gut health and brain health are intertwined, and that there may be common mechanisms driving the parallel epidemics of obesity, inflammatory gut conditions and behavioral disorders.
https://medicalxpress.com/news/2019-01-common-food-additives-anxiety-related-behavior.html
Recent AVXL News
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
- Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference • GlobeNewswire Inc. • 11/26/2025 12:30:00 PM

